In this engaging discussion, G. Caleb Alexander, MD, MS, from Johns Hopkins Bloomberg School of Public Health, and Hemalkumar B. Mehta, MS, PhD, dive into the burgeoning use of glucagon-like peptide-1 (GLP-1) agonists among bariatric surgery patients. They reveal that 14% of these patients initiate GLP-1 therapy due to insufficient weight loss, highlighting prescription trends and the evolving guidelines in this field. The conversation also emphasizes the vital need for better communication between patients and physicians about weight management post-surgery.
